Day: July 6, 2023

CEO Provides Brief Market Commentary GLYFADA, Greece, July 06, 2023 (GLOBE NEWSWIRE) — Seanergy Maritime Holdings Corp. (the “Company” or “Seanergy”) (NASDAQ: SHIP) announced today that it has repurchased 362,161 common shares, or approximately 2% of its issued and outstanding shares, at an average price of approximately $4.35 per share pursuant to its previously announced share repurchase program. The average share repurchase price represents approximately a 11.2% discount from the closing price of July 5, 2023. Moreover, the Company entered into a 12-month bareboat charter agreement with an unaffiliated third party in Japan for a 2011-built Newcastlemax dry bulk vessel of 207,855 dwt built at Nantong COSCO KHI Ship Engineering Co Ltd (NACKS). Pursuant to the terms of the bareboat charter, Seanergy has advanced a down payment...

PLEASANTON, Calif., July 06, 2023 (GLOBE NEWSWIRE) — ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (“OSA”), will report its strong second quarter financial results prior to market open on Thursday, August 3, 2023. ProSomnus Chief Executive Officer, Len Liptak, and Chief Financial Officer, Brian Dow, will host a conference call at 5:30 am PT / 8:30 am ET. Management will provide an update on the Company’s commitment to commercial performance and ongoing clinical data demonstrating positive patient outcomes for ProSomnus’s patient-preferred, first-line precision oral appliance therapy for the significant patient population afflicted with OSA. Investor Call Dial-In InformationInterested parties may register for the conference call using the following link ProSomnus Q2 2023 Conference...

NEW YORK and LONDON, July 06, 2023 (GLOBE NEWSWIRE) — Navigator Holdings Ltd. (“Navigator” or “Company”) (NYSE: NVGS), the owner and operator of the world’s largest fleet of handysize liquefied gas carriers, is pleased to announce the publication of its 2022 Environmental, Social and Governance (ESG) Report (the “ESG Report”) and launch of its new ESG strategy ‘Fueling the Future’ (the “ESG Strategy”). Building on its progress in ESG over the last few years, the ESG Strategy strengthens Navigator’s corporate strategy to connect the world today and deliver a sustainable tomorrow. Developed with support from Boston Consulting Group and Mærsk Mc-Kinney Møller Center for Zero Carbon Shipping, Navigator’s ESG Strategy identifies three ‘lighthouse’ focus areas, where the Company believes that, through its capabilities, it can make the...

NFI Group Inc. – BYD–Alexander Dennis Enviro200EV for Go-Ahead London NFI Group Inc. – BYD–Alexander Dennis Enviro200EV for Go-Ahead LondonLARBERT, United Kingdom, July 06, 2023 (GLOBE NEWSWIRE) — (TSX: NFI, OTC: NFYEF, TSX: NFI.DB) NFI Group Inc. (“NFI” or the “Company”), a leading independent bus and coach manufacturer and a leader in electric mass mobility solutions, subsidiary Alexander Dennis Limited (“Alexander Dennis”) and BYD UK jointly announced today that their electric vehicle partnership has taken a repeat order from Go-Ahead London for a further 141 battery-electric buses, taking the total to be delivered to the operator during 2023 to 299 vehicles. This new order follows Go-Ahead London’s success in winning contracts for bus routes tendered by Transport for London. Transport for London’s vision is...

6 July 2023 Biodexa Ltd(“Biodexa” or the “Company”) Publication of Manuscript from the PNOC015 (a.k.a. MTD-201) Study in Patients with Diffuse Midline Glioma (DMG) Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of products aimed at primary and metastatic cancers of the brain, is pleased to announce the publication of the results of an investigator-initiated Phase I study PNOC015 (also known as MTD-201) of MTX110 in the treatment of pediatric patients with DMG (formerly known as Diffuse Intrinsic Pontine Glioma, or DIPG) in the Journal of Neuro-Oncology (NCT 03566199). The study recruited seven pediatric patients with confirmed diagnosis of DMG, after radiation therapy. Convection Enhanced Delivery (CED) of MTX110 at doses escalating from 30µM to 90μM was performed, with a total...

Press Release no. 02/2023 cBrain to test F2 Climate Software with the Kenyan National Environmental Management Authority (NEMA)Copenhagen, 6. July 2023We are pleased to announce that cBrain has signed an agreement to deliver an F2 based environmental inspection solution for the Kenyan National Environmental Management Authority (NEMA). This is the first project with NEMA. The project goal is to provide NEMA with a platform to manage environmental auditing. The project will serve as verification of how F2 Climate Software solutions delivered for the Danish environmental protection agency can be copied and adapted for NEMA and other environmental protection agencies. The project scope includes that NEMA will go live with the adapted F2 solution, to ensure real working experiences. cBrain believes that a successful test with NEMA can...

Lyell Immunopharma to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform in its T cell product candidates targeting solid tumors. ROCKVILLE, Md., July 06, 2023 (GLOBE NEWSWIRE) — MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, today announced the signing of a strategic platform license (SPL) with Lyell Immunopharma, Inc., a clinical stage T cell reprogramming company. Under the terms of the agreement, Lyell Immunopharma obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform. In return, MaxCyte is eligible...

HAMPTON, N.J., July 06, 2023 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in the Company’s Phase 2 subcutaneous study of barzolvolimab in eosinophilic esophagitis (EoE). EoE is the most common type of eosinophilic gastrointestinal disease, a chronic inflammatory disease of the esophagus. Several studies have suggested that mast cells may be an important driver in this disease. Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity, which is required for the function and survival of the mast cell. “There is a growing body of literature that suggests that eosinophilic esophagitis may be a misnomer for this difficult to treat disease and that other cell types,...

Key study results Key efficacy endpointsEblasakimab is the first biologic in moderate-to-severe atopic dermatitis to demonstrate a competitive efficacy profile with once-monthly dosing from initiation comparable to once every two weeks, supporting advancement to Phase 3. 600mg eblasakimab dosed once every four weeks in the TREK-AD study met the primary endpoint with statistical significance, with 62.7% of patients achieving EASI-75, 34.1% reaching EASI-90 and 31.2% achieving vIGA-AD of 0 or 1. Regimens dosing once every two weeks also met the primary endpoint with statistical significance, as well as meeting key secondary endpoints. Unique loading dose regimen observed to deliver rapid onset of action with statistically significant improvement in EASI score by week 4. Eblasakimab was generally well-tolerated at all dose levels, with...

HORSHAM, Pa., July 06, 2023 (GLOBE NEWSWIRE) — STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced that it has completed the refinancing of its existing debt agreement with a new facility from MidCap Financial (MidCap). The new debt facility consists of a refinancing of the existing $8.0 million term loan and an additional $7.0 million tranche funded at closing. The Company also has the option to receive an additional $5 million tranche in 2024. “We are pleased to complete this debt refinancing and enter into a new term agreement with MidCap,” commented Chris Lesovitz, Chief Financial Officer of STRATA Skin Sciences. “We have increased our cash position to approximately $10...